Purpose To mimic the physicochemical selectivity of the blood-brain barrier (BBB) and to predict its passive permeability using a PAMPA model based on porcine brain lipid extract (PBLE 10%w/v in alkane). Methods Three PAMPA (BD pre-coated and PBLE with 2 different lipid volumes) models were tested with 108 drugs. Abraham solvation descriptors were used to interpret the in vitro-in vivo correlation with 282 in situ brain perfusion measurements, spanning over 5 orders of magnitude. An in combo PAMPA model was developed from combining measured PAMPA permeability with one H-bond descriptor. Results The in combo PAMPA predicted 93% of the variance of 197 largely efflux-inhibited insitu permeability training set. The model was cross-validated by the "leavemany-out" procedure, with q 2 =0.92±0.03. The PAMPA models indicated the presence of paramembrane water channels. Only the PBLE-based PAMPA-BBB model with sufficient lipid to fill all the internal pore space of the filter showed a wide dynamic range window, selectivity coefficient near 1, and was suitable for predicting BBB permeability. Conclusion BBB permeability can be predicted by in combo PAMPA. Its speed and substantially lower cost, compared to in vivo measurements, make it an attractive first-pass screening method for BBB passive permeability.
ABBREVIATIONS
(ε/δ) 2 porosity of paramembrane aqueous pores divided by the length of the water-filled channels in thin PAMPA-BBB membranes (δ~0.01 cm) ABL aqueous boundary layer-thin stagnant layer adjacent to the surface of a membrane BLM bilayer lipid membrane, unilamellar barrier formed from egg lecithin D aq aqueous diffusivity (cm 2 ·s −1 ) DRW dynamic range window: DRW=log P ABL -log P para h ABL ABL thickness (cm) in combo methodology where a measured property (e.g., PAMPA permeability coefficient) is aditively "combined" with a calculated (in silico) descriptor (e.g., H-bond potential) P ABL ABL permeability coefficient (cm·s BBB intrinsic permeability coefficient of the uncharged-form of permeant; for ionizable compounds, P o in situ =P c in situ (10 ±(pH-pKa) +1), '+' for acids, '−' for bases PAMPA-BBB parallel artificial membrane permeability assay, based on PBLE formulation PBLE porcine brain lipid extract PS capillary permeability-surface area product (mL·s −1 ·g −1 ), determined from the uptake rate constant (K in ) using Crone-Renkin equation: K in =F pf ( 1-e -PS/Fpf ), where F pf is the regional cerebral flow of perfusion fluid (mL·s
SC selectivity coefficient; slope in the log-log in vitro-in vivo correlation plot
INTRODUCTION
The persistent difficulty of delivering therapeutic molecules across the blood-brain barrier (BBB) to achieve optimal central nervous system (CNS) exposure continues to be a formidable challenge in the neuropharmaceutical industry. During drug discovery, costly in vivo measurements of brain penetration (1) (2) (3) (4) (5) (6) (7) (8) are impractical, given the large number of molecules to test. This necessitates an ongoing search for simple and cost-effective in vitro (9) (10) (11) (12) (13) (14) and in silico (15) (16) (17) (18) models to predict the BBB permeation (rate of brain penetration) and other important properties relevant to successful CNS delivery (1) . The chemical selectivity of the barrier microenvironment governing the passive permeation of drugs across the BBB can be probed with simple isotropic solvent/water partition (e.g., octanol, hexadecane, octanol-hexadecane) models (19) (20) (21) , with egg lecithin bilayer lipid membrane (BLM) models (22, 23) , with parallel artificial membrane permeability assays (PAMPA) (9) (10) (11) (12) (13) (14) , and with in vitro brain microcapillary endothelial cell (BMEC) models originating from different species (24) (25) (26) (27) (28) . The in vivo benchmark against which the simpler permeability models are often compared is the in situ rodent brain perfusion technique (11, (29) (30) (31) (32) (33) (34) (35) (36) .
Anderson and coworkers (22, 23) have found that 1,9-decadiene/water partition coefficients precisely mimic the chemical selectivity of the egg lecithin BLM barrier domain, from comparisons with the intrinsic permeability coefficients, P o BLM , of a series of substituted toluic and hippuric acids.
(P o BLM refers to the permeability of the bilayer membrane to the uncharged form of an ionizable molecule.) The plot of log P o BLM as a function of the logarithm of the partition coefficient for the series of toluic acids had the slope 0.99± 0.04 and intercept −0.17±0.12 (r 2 =0.996). Often, the slope in such a log-log plot is called the selectivity coefficient, SC. A value~1 suggests that the microenvironment of the ratelimiting unilamellar BLM barrier domain closely matches that of the isotropic reference solvent. Based on a linear free energy relationship (LFER) analysis, it was possible to assign quantitative fragment contributions in the homologous series of weak acids studied. To date, it has not been demonstrated to what extent the egg lecithin unilamellar bilayer membrane model matches the chemical selectivity of the more complex BBB permeation barrier.
Levin (19) noted that the octanol-water partition coefficients, log P OCT , correlate with in situ rat brain perfusion intrinsic permeability coefficients, P o in situ . In that and a number of other studies, the reported log P o in situ as a function of log P OCT plots generally indicated SC~0.5, suggesting that octanol only partly matches the chemical selectivity of the rate-limiting microenvironment controlling passive BBB permeability. Past comparisons have been limited to small sets of drugs, due to the relative scarcity of in situ brain perfusion measurements for drug molecules prior to 2003 (15) . Di et al. (9) introduced the PAMPA model based on porcine brain lipid extract (PBLE) dissolved in dodecane (2%w/v) and demonstrated that drug molecules can be binned into CNS+ and CNS-activity classes. In a follow-up study (10) , a comparison of the PBLE-based PAMPA and the in situ rat brain perfusion permeability coefficients reported by Summerfield et al. (35) tentatively suggested appreciable chemical selectivity in the PAMPA model, with r 2 =0.47.
Mensch et al. (12) tested four PAMPA models for predicting the brain-plasma ratio, log BB. The CNS+/-discrimination was confirmed with the Di et al. model. The ability to predict log BB was comparable with the PBLEand much simpler dioleoylphosphatidylcholine (DOPC)-based PAMPA models (r 2 =0.63 and 0.73, respectively). An in combo PAMPA (measured permeability "combined" with calculated H-bond descriptors) study based on a concentrated lecithin lipid mixture (20% w/v in dodecane) membrane indicated a high linear correlation (r 2 =0.92) in the prediction of in situ rodent brain perfusion permeability (11) . However, when just the lecithin PAMPA permeation values were compared to those of the in situ data, SC=0.49 for the training set (r 2 =0.56), suggesting that although the model could be made highly predictive by augmenting with in silico "booster" descriptors based on the LFER solvation model of Abraham (16) , the lecithin-based PAMPA model alone did not well match the microenvironment of the BBB.
In this study, we developed a new PBLE-based PAMPA model, using a five-fold higher lipid concentration in a more viscous alkane solvent than dodecane and with thinner membranes, compared to that used by Di et al. (9, 10) . PAMPA-BBB intrinsic permeability values for 108 compounds were correlated to those of 197 published in situ rodent brain perfusion measurements, the largest such reported set to date. We were able to demonstrate a remarkably high match between the physicochemical selectivity of the new PAMPA-BBB and the in situ data, with SC=0.97 for a series of weak-base drugs thought to permeate passively. The nature of this physicochemical selectivity was characterized in terms of the Abraham (16) linear free energy solvation descriptors. For newly measured compounds with unknown mechanism of transport, having a reliable prediction of passive BBB permeability could serve to indicate the presence of carriermediated processes. This was investigated with an additional 85 in situ rodent brain perfusion measurements (not used in the model training) of cases where efflux or active transport was suspected.
MATERIALS AND METHODS

Chemicals and Materials
Most of the chemicals in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used as received. Analytical-grade bremazocine, buspirone, p-F-phenylalanine, indinavir, ritonavir, saquinavir, and SNC-121 were kindly provided by Astrazeneca (Wilmington), as described elsewhere (11) . Alfentanil and meperidine were generous gifts from Prof. Per Artursson (Uppsala University) and Dr. Manfred Kansy (Roche, Basel), respectively. Imitanib mesylate was purchased from Selleck Chemicals LLC (Houston, TX). Rosuvastatin acid was extracted from a tablet (AstraZeneca) containing 20 mg of the drug as a calcium salt. PAMPA-BBB lipid (PBLE) was obtained from pION (PN 110672) and was stored at −20°C when not used. BD pre-coated PAMPA plates (37) were purchased from BD Biosciences (Bedford, MA, USA; PN 353015-LOT 02059) and were stored at −20°C prior to use. The pH of the assayed donor solutions was adjusted with a universal buffer (pION Prisma TM HT, PN 100151). A buffer solution at pH 7.4 containing a chemical scavenger to simulate tissue binding and maintain sink conditions (pION BSB-7.4 buffer, PN 110674) was used as the receiver solution.
pK a Determination
The potentiometric Gemini Profiler TM (pION) instrument was used to determine ionization constants of amoxapine, atomoxetine, chlorambucil, citalopram, domperidone, doxorubicin, ergotamine, ethosuximide, fluoxetine, fluphenazine, galanthamine, imitanib, lamotrigine, loxapine, mirtazapine, oxycodone, pergolide, perphanazine, phenelzine, rosuvastatin acid, sumatriptan, trazodone, trifluoperazine, venlafaxine, vinblastine, and vincristine at 25±0.5°C and 0.15 M ionic strength (KCl). General details of the procedure have been described elsewhere (38) (39) (40) . Electrode calibration was performed in situ, concurrently with the pK a determination (39) . This is a substantial improvement in comparison to the traditional procedure of first doing a "blank" titration to determine the four AvdeefBucher pH electrode parameters (40) , before proceeding to the pK a determination.
PAMPA Method
Data Collection
The PAMPA Evolution instrument from pION INC (Woburn, MA, USA) was used in this study. The 96-well microtitre plate "sandwich" (pION, PN 110212, pre-loaded with magnetic stirrers) filters were automatically coated with a 10% (w/v) alkane solution of PBLE. In the study, we also used BD pre-coated (4%w/v DOPC in 1 μL hexadecane per well) plates (37) . For most of the compounds, UV sensitivity was good, and the typical concentrations were about 50-150 μM prepared from 10-30 mM DMSO stock solutions. DMSO-free solutions were prepared for some of the compounds (buspirone, tolbutamide, U69593, fentanyl, ritonavir, clozapine, deltorphin II, DPDPE, galanthamine, indinavir) to improve on UV sensitivity in the 210-240 nm part of the spectrum. Sample concentrations in the buffer solutions for the compounds with low-UV absorption were about 500-1000 μM (e.g., DPDPE, etoposide, ethosuximide, L-DOPA). The donor solutions were varied in pH (NaOH-treated universal buffer), while the receiver solutions had the same pH 7.4. The collection of data under the varied gradient-pH conditions enabled the determination of the intrinsic permeability coefficients, the diffusion through aqueous pores in the PAMPA-BBB membrane, and the aqueous boundary layer (ABL) effects (13, 41, 42) . The receiver solutions contained a surfactant mixture ("lipophilic sink") to mimic tissue binding (38) . Since the BD precoated filters started to leak visibly on exposure to the "sink" buffer, the sink-forming additive was removed from the buffer when the BD plates were used. For lipophilic compounds, vigorous stirring was employed in the assay, with stirring speed set to produce an ABL thickness of about 60 μm, to minimize the ABL contribution to the measured permeability. The PAMPA sandwich was assembled and allowed to incubate for 30-60 min with lipophilic molecules (e.g., amitriptyline, chlorpromazine, loperamide, sertraline, probenecid and verapamil), and 15 h for hydrophilic molecules (e.g., galanthamine, DPDPE, deltorphin II, indinavir), in a controlled-environment chamber (pION Gut-Box TM , PN 110205) with a built-in magnetic stirring mechanism. The BD pre-coated plates were not stirred, since the magnetic stirrers used here could not be fitted in the provided plates. Both the donor and receiver wells were assayed for the amount of material present, by comparison with the UV spectrum (210-500 nm) obtained from a reference standard. Permeability values were corrected for membrane retention (38) .
To test the stability and integrity of the PAMPA membrane barrier as a function of the amount of lipid solution deposited, assays were performed with 1.5 μL ("Type I" assay in Table II ) and 3 μL ("Type II") lipid volume depositions on the filters, as well as with the 1 μL/ well BD pre-coated plates (37) . In the Type I case, a volatile solvent was mixed with the lipid formulation (to minimize volumetric errors in small-volume dispensing by the robotic instrument) and allowed to evaporate before the start of assay.
PAMPA-BBB Permeability Equation
The computational model assumed that the PAMPA effective permeability, P e , can be expressed by its three underlying components: P ABL , P o , and P para (aqueous boundary layer, intrinsic transmembrane, and paramembrane, respectively; cf. Abbreviations). The P para term describes the diffusion of permeant through water-filled channels hypothesized to form in very thin PAMPA-BBB membrane barriers and in the BD pre-coated filters. This term was added to account for the observed lipophilicityindependent permeation of charged species in thin-membrane barrier.
A weighted nonlinear regression method (38, 39, 43, 44 ) was used to determine the P ABL , P o , and P para coefficients from a series of P e measurements performed at different values of donor-well pH (acceptor-wells at pH 7.4), according to the equation:
From the three refined constituent permeability coefficients, the thickness of the ABL, h ABL , and the porosity-pathlength ratio (43, 44) , (ε/δ) 2 85 values were designated as the non-trained "external" set. These were selected as possibly being from substrates of carrier-mediated or actively transported processes, based on the following criteria. In studies where both knockout (KO)/efflux-inhibited and wild-type (WT)/ uninhibited rodent measurements were reported, the KO/ efflux-inhibited values directed to the training set (n=197), but the corresponding WT/uninhibited paired values were added to the external set (n=85), unless the WT/uninhibited values were either within a factor of three of the KO/ inhibited or were very high (P o in situ > 0.01 cm/s), in which case both values were used in training. Thus, the external set was not viewed as a rigorous model validation set, but was rather used to indicate whether actively transported molecules could be identified by their deviations from the predicted passive values (negative/positive deviations indicating efflux/uptake transport processes, respectively). Table I contains physical properties of the 108 selected molecules encompassing the 282 (197+85) in situ brain perfusion measusrements used in the study. The interlaboratory variance in permeability measurements are estimated to be no less than ±0.2 log units (e.g., log P o in situ ± SD values of antipyrine, colchicine, and sucrose 
Model Validation
A validation strategy was applied to the 197 measurements in the training set, based on the "leave-many-out" (LMO) cross-validation procedure (20% of the measurements randomly excluded in 100 different repeated combinations), where a cross-validated q 2 was used to assess model predictivity. The commercial statistical software is briefly described below.
Linear Free Energy Relation (LFER) Descriptors "Boosting" PAMPA Measured Values
Abraham's linear free energy relations (LFER) applied to a BBB permeability model may be stated as (16) log P
where c 0 ...c 5 are the multiple linear regression (MLR) coefficients, and where α is the solute H-bond acidity, β is the solute H-bond basicity, π is the solute polarity/ polarizability due to solute-solvent interactions between bond dipoles and induced dipoles, R (dm 3 mol −1 / 10) is the excess molar refraction, which models dispersion force interaction arising from pi-and n-electrons of the solute, and V x is the McGowan molar volume (dm 3 mol -1 / 100) of the solute.
Equation 2 uses intrinsic BBB permeability values, P o in situ , rather than PS values, because the Abraham molecular descriptors have been developed for uncharged species in the LFER approach, and so it was decided to convert all effective permeability values (in situ PS, PAMPA P e ) to intrinsic values, P o in situ and P o , in order to develop the LFER model. In the case of zwitterions, the conversion was to the P ± form (39) . This may seem unnecessary, given that the environment of the BBB is very close to pH 7.4. However, the transformation is solely a computational strategy, in order to take full advantage of the Abraham descriptors. In effect, by these transformations, we have adapted the Abraham molecular descriptors for charged molecules (11) .
In addition to the LFER model, we explored how well PAMPA-BBB measurements, augmented with one (or two) of Abraham's molecular solvation descriptors, can predict passive intrinsic permeability values of the in situ data. The combination of measured PAMPA-BBB and a calculated LFER descriptor defines the in combo method:
where A(c 2 ,c 3 ) is a linear function of one/two Abraham descriptors. The usefulness of such an approach has been demonstrated elsewhere (11, 13) . Fewer MLR coefficients are necessary in Eq. 3, compared to Eq. 2, because the PAMPA-BBB P o already encodes for some of the properties of the microenvironment of the in vivo barrier that are related to permeation. The best prediction model was validated by testing its ability to predict BBB permeability of data not used in the training set.
The octanol-water partition coefficients, log P OCT , some of the pK a s (cf., Table 1 ), and the Abraham descriptor calculation, as well as the computational modeling, used the Algorithm Builder V1.8 and ADME Boxes V4.9 computer programs (17) from ACD/Labs (Toronto, Canada). The pCEL-X program (pION) was used to predict PAMPA permeability coefficients from 2-D structural input.
Selectivity Coefficients and the Solubility-Diffusion Theory
According to the solubility-diffusion theory (22, 23) , the passive permeability of the BBB, P o in situ , can be estimated as the product of the partition coefficient of the ratelimiting BBB boundary domain and water, PC BBB/w , and the BBB-phase diffusivity of the solute, D BBB , divided by the thickness of the barrier domain, δ BBB , which may be stated in logarithmic form as
Diffusivity in the rate-limiting membrane phase is expected to be proportional to the minimum cross-sectional area of the solute (38, 43, 91) . Using a Collander-like equation (22, 23) , the PC BBB/w is expected to be linearly related to the PAMPA-lipid/water partition coefficient, PC PAMPA/w , as log PC BBB/w =a+SC· log PC PAMPA/w . The Collander relationship, along with Eq. 4 applied to the PAMPA-BBB intrinsic permeability, P o , produces the relationship,
where the constant intercept term, i=a+log (D BBB / δ BBB ) -SC • log (D PAMPA / δ PAMPA ). If the model PAMPA-BBB lipid precisely mimics the physicochemical selectivity of the boundary domain region in the BBB, then the value of SC=1 and i=a, the intercept term from the Collander equation.
RESULTS AND DISCUSSION
pK a Determinations For the purposes of this study, four classes of drugs were defined based on the pK a values used. "Bases" were defined as molecules with a predominant (≥ 50%) positive charge at pH 7.4; "acids" had a predominantly negative charge; "neutrals" were predominantly uncharged; "zwitterions" were ampholytes with the predominant zwitterionic form. These were operational labels used to partition the compounds into four charge classes for the prediction model development.
PAMPA-BBB Measurements
Table II lists the refined PAMPA intrinsic permeability values (log P o ), the aqueous boundary layer permeability (log P ABL ), and the "water-pore" permeability coefficients (log P para ). Also listed are the calculated membrane permeability values at pH 7.4, P m 7.4 . Figure 1 shows a sampling of the effective permeability, P e , coefficients used to determine these constituent permeability coefficients by regression analysis, based on Eq. 1.
In this study, the permeability values based on BD-and PBLE-coated plates were compared under otherwise identical conditions for 22 compounds (P o BD data summarized in Fig. 2a) . The frames in Fig. 1a −d were performed with 3 μL-coated filters, using the PBLEbased PAMPA-BBB model. The frames in Fig. 1e −h correspond to the 1 μL-pre-coated BD plates. Since the lipid barriers are thinner in the latter case, values of P o BD are somewhat larger than those of P o PBLE , as indicated in Fig. 1 . This is to be expected, due to the decreased resistance of thinner lipid barriers. However, the near absence of pH dependence in the BD-plate data was surprising and unanticipated (37) .
The three bases in Fig. 1(a, b, c, e, f, g ) have ascending membrane permeability (dashed) hyperbolic curves, P m , with increasing pH. The acid (Fig. 1d, h) shows a converse descending behavior. The maximum point in the log P mpH curves corresponds to the intrinsic permeability coefficient, log P o .
The best-fits of Eq. 1 to the P e data (circle symbols) are represented by the sigmoidal solid curves. Just above the maximum leveling in the solid sigmoidal P e curves is the value of the ABL permeability (dotted horizontal lines). This is the rate-limiting ABL barrier to the membrane permeability for lipophilic compounds, and values of P m greater than P ABL cannot be directly measured. Just below the minimum leveling in the solid sigmoidal P e curves are the P para permeability values corresponding to the shunting aqueous pores (horizontal dot-dash lines). Values of P m less than P para cannot be measured directly. Hence, the available dynamic range window (28), DRW, is bounded at the top by P ABL and at the bottom by P para . As can be seen in Fig. 1 (right frames) , the DRW is very narrow when BD plates are used ("1 μL lipid"). The DRW is substantially widened in the case of less leaky filters, with solutions that Fig. 1 The log permeability vs. pH plots of four of the 108 molecules determined by the PAMPA-BBB method. The a−d frames are based on 3 μL PBLE lipid coated filters, while the e−h frames are based on the 1 μL 4%w/v DOPC in hexadecane BD pre-coated filter plates. The pH was varied to assess the contribution of the aqueous boundary layer and the shunting effect of the paramembrane aqueous pores. The best-fit of the log form of Eq. 1 to the measured effective permeability data, P e vs. pH, are represented by the solid curves, and the paramembrane-and ABL-corrected log P m vs. pH curves are represented by dashed curves. The dot curves correspond to the log P ABL values, and the dot-dash curves correspond to the paramembrane permeability, log P para . The maximum point in the log P m curves corresponds to the intrinsic permeability coefficient, log P o , which characterizes the permeability of the neutral form of an ionizable molecule. The intersections of the horizontal and the diagonal tangents occur at pH values corresponding to the pK a in the dashed curves. The dynamic range window, DRW, is the permeability gap defined by log P ABL at the top and log P para at the bottom.
are adequately stirred, as in the case of the "3 μL lipid" PAMPA-BBB model (Fig. 1a−d) .
In the case of the effective permeability of charged species, the significant participation of ion-pair permeability was ruled out, since the P para values are not proportional to the lipophilicity of the compounds, but seem to be nearly constant for a given stirring speed, which is consistent with the diffusion of compounds through aqueous pores in the PAMPA membrane. Table III summarizes the average permeability values for the three PAMPA models considered in this study: BD Pre-coated, Type I PAMPA-BBB and Type II PAMPA-BBB, which had filters coated with 1.0, 1.5, and 3.0 μL lipid volumes, respectively. Stirred (average log P ABL −3.2 to −3.3) and non-stirred (average log P ABL −4.3 to −4.8) assays were considered. The thickness of the ABL, h ABL = 2000±791 μm, in the PBLE unstirred assays was about half of the value observed with the BD assays, h ABL =3909± 1405 μm; the lower values in the PBLE system are due to the effect of the "sink" buffer (41) . The average values of P para from the three models indicated aqueous pore permeability that appeared to depend on the lipid thickness of the PAMPA membrane barrier. For unstirred plates, the porosity (ε in Table III) of the BD pre-coated plates was determined to have the average value of 0.84%, compared to 0.29% (1.5 μL) and 0.04% (3.0 μL) PBLE-based lipidcoated plates. The higher the aqueous channel porosity, the greater the transmembrane aqueous pore diffusion of drug species. As can be seen, the dynamic range window (DRW), which is defined by log P ABL -log P para , in Fig. 1e −h is severely lessened by the high porosity (0.84%), compared to that of the Fig. 1a−d frames, where the porosity is much lower (0.04%). Stirring increases the porosity (Table III) . Unexpectedly, the increase in membrane porosity is less with the 1.5 μL coated plates (0.29 → 0.33%) than the 3.0 μL coated plates (0.04 → 0.47%). Theoretically, the lipid volume capacity of the 70% porosity PVDF filters is 2.6 μL (88), so the 3 μL volume represents a slight excess over the internal volume capacity of the filter. We were not able to stir the BD plates (cf., Materials and Methods Fig. 1 (continued) section) to see how much porosity would increase, although an increase in porosity would be expected.
From these results, it is prudent only to use aggressive stirring with highly lipophilic compounds (to increase the DRW), but not with compounds expected to have low permeability coefficients, since high values of P para would have a masking effect on the PBLE membrane contribution (28, 43) . Of the 22 drugs tested with the BD plates, three compounds could not be reliably processed, evidently, since P m <P para over the tested pH range. Table II indicates four types of permeability data used in the BBB modeling: I, II, I/II and DS. Type II data were collected with PAMPA plates that had 3 μL lipid-volumecoated filters. Type I/II data were collected twice: once with 1.5 μL coated filter plates and once with 3 μL coated filter plates. Comparison of the two sets of data indicated the highly collinear relationship: log P o (3μL) =−0.22(±0.14)+ 1.00(±0.04) log P o (1.5 μL)
, r 2 =0.96, s=0.30, F=659, n=31. The antilog of the intercept indicates that the thinmembrane permeability coefficients were nearly twice as large as the thick-membrane values, which is consistent with the additivity of membrane barrier resistance. Only the 3 μL data are reported in Table II under the I/II category. The data reported in Table II as Type I were collected under the 1.5 μL conditions but scaled to match the 3 μL setting, using the above correlation equation. The Type DS data in Table II represent compounds not available to us during this study, but whose permeability had been originally determined by us, using the Double-Sink PAMPA model. In this study, the PAMPA-DS values were transformed by pCEL-X to the "3 μL" PAMPA-BBB basis. These molecules were only used as non-training compounds in the study, since their precision is not expected to match that of the directly-measured PAMPA-BBB data.
Selectivity Coefficients (SC)
One of the overall objectives of the study was to identify a PAMPA-BBB model that has a selectivity coefficient, SC1
. We have nearly succeeded in this study. (Where the model fell short, the in combo technique led to dramatic improvements, as described below.) Figure 2 shows how well the various simple models measure up against the in situ brain perfusion intrinsic permeability values, log P o in situ . The frames in the figure are ranked by SC values. The two lowest SC value models are the BD pre-coated (PAMPA-BD) and the log P OCT , with SC~0.6. The 4% w/v DOPC in dodecane PAMPA-BD system is slightly more lipophilic than log P OCT and considerably more lipophilic than the BBB (22, 23) . In Fig. 3 , apparently the lower the value of SC, the higher the scatter in the data, as indicated by the calculated r 2 and standard deviation, s. This may support the hypothesis that when the microenvironment controlling passive diffusion in the BBB is better matched by a simple model, the quality of the prediction improves. PAMPA-BD (Fig. 2a) appears to perform better than log P OCT (Fig. 2b) , although the number of compounds tested with the former model is not large.
The egg lecithin bilayer lipid (BLM) model (Fig. 2d ) performed surprisingly well, although the number of reported measurements of P o BLM for compounds whose P o in situ values were also reported was very small, and the compounds were not drug-like. It could be posited that the BLM model (100% lecithin) is the asymptotic limit of the BD model (4% lecithin) and that the presence of 96% hexadecane in the latter model contributes to lowering SC from 0.76 to 0.55.
The performance of the PAMPA-BBB model (10%w/v PBLE in alkane) based on 3 μL lipid deposition is quite remarkable, albeit primarily for weak bases (Fig. 2e) . The value of SC=0.97, near-zero intercept, and r 2 =0.84, based on 85 training set weak base drugs, was a promising lead in the search for a more-encompassing (in combo) model. Figure 3 shows the log-log correlation between the rodent data and the PAMPA-BBB model for the four charge classes of drugs for the 197 training-set measurements. The overall selectivity coefficient, SC=0.87, with r 2 =0.77 and s=0.76, might have suggested a highly predictive model. But when the measurements are scrutinized by charge classes, a more complicated view unveils. The selectively predictive bases (positively charged), indicated by blue points in Fig. 3 , are associated with SC=0.97±0.05 (r 2 = 0.84). The acids (negatively charged), indicated by red points, show SC=1.08±0.25 (r 2 =0.42). The green points are neutral compounds, which show SC=0.55±0.07 (r 2 = 0.46). The orange points are zwitterions with SC~0 (r 2~0 ). As can be seen, the BBB microenvironment affecting passive permeability is not well matched by the neutral and zwitterionic drugs. For zwitterions, there was no evident correlation between the two permeability scales. As the discussion below indicates, it was possible to improve the correlation for each of the deficient classes, up to r 2 = 0.61-0.88 (Table IV) , by using the in combo technique.
PAMPA-BBB Selectivity Coefficients by Charge Classes
Abraham LFER and In Combo PAMPA Models
The Abraham LFER solvation descriptors have been applied in predictions of log P OCT (98) , as well as BBB permeability-related properties, log PS (16, 73) , log BB of a diverse set of compounds (92) and ampholytes, including zwitterions (99) . Table IV lists Such an LFER analysis (Table IV) may suggest some potentially useful compound promotion criteria, which may help medicinal chemists modify/select test compounds to enhance passive BBB permeation. For example, for enhanced permeation, one may select (a) small zwitterions, large bases (V x effect); (b) acids with high dispersion forces (more polarizable piand n-electrons), bases with low dispersion forces (R effect); (c) neutrals with high dipole moments (solute-solvent interactions), low dipole moment zwitterions/bases/acids (π effect); (d) zwitterions/bases with high H-bond donor strength, acids with low H-bond donor strength (α effect); (e) zwitterions with high H-bond acceptor strength, acids with low H-bond acceptor strength (β effect).
The in vitro-in vivo (IVIV) relationship between the PAMPA-BBB and the in situ brain perfusion models can also be framed in terms of the Abraham descriptors. Figure 4 displays the quintet of Abraham MLR coefficients in polar plots to facilitate the IVIV model comparisons. As can be seen, the two pentagons in Fig. 4 for bases are nearly congruent. The relationships for the other charge classes show characteristic differences. For example, for acids, the in situ intrinsic permeability greatly decreases with increasing β (H-bond acceptor) content in the molecule. On the other hand, the PAMPA-BBB model for acids is less Fig. 3 In vitro-in vivo correlation between in situ rodent brain perfusion intrinsic permeability and PAMPA-BBB (3 μL/well 10%w/v PBLE in alkane) intrinsic permeability. a See text and Abbreviations for definitions. Octanol-water partition descriptors were determined by Abraham et al. (98) . log P o in situ (in combo)=c 0 +c 1 log P o +c 2 (α±β), where P o is the intrinsic permeability determined from the PAMPA-BBB (Type II) model. The linear correlation coefficient is r 2 ; s=standard deviation; F="F" statistic; n = number of training set compounds in the group. Data partitioning is determined on the basis of predominant charge at pH 7.4 (cf., Table 1 ).
sensitive to values of β. The opposite β trend appears to hold for neutral molecules in Fig. 4 . A dramatic discordance is indicated for zwitterions in Fig. 4 , with the prediction that high β content in the molecule greatly enhances permeation in PAMPA-BBB and also somewhat facilitates permeation in vivo. One plausible explanation for the differences in the IVIV behavior in acids and zwitterions is that H-bond donors in the in vivo microenvironment facilitate transport for these two charge classes. There may be unsuspected carrier-mediated transport processes in the in vivo data for the acids and zwitterions selected in this study. The training set of molecules was chosen to minimize efflux contributions, but no explicit filtering was selected to identify facilitated transport (other than not using simple amino acids and dipeptides).
Whatever the nature of the IVIV discordance for the acids and zwitterions between the two permeability systems, the in combo technique can be used to minimize the differences to improve the global predictability of the PAMPA-BBB model (11, 13) . The bottom third of Table IV indicates the in combo PAMPA-BBB MLR coefficients which improve IVIV. For bases, only a slight improvement was achieved (r 2 increased from 0.84 to 0.86) by introducing the α descriptor, which mainly drove the −0.14 intercept (Fig. 2d) to −0.01. For the two charge classes with SC well below unit value (neutral, zwitterion), a search procedure revealed that two Abraham-based descriptors, α+β and α-β can dramatically enhance the predictability of the PAMPA-BBB model. For acids, a contribution of 2.54-0.64(α+β) to experimentally determined log P o values raises r 2 from 0.42 to 0.61 and lowers s from 0.67 to 0.56. Just one added variable, (α+β), improves the IVIV for acids ("sum" Hbond effect). The zwitterion model can be made predictive by just using one variable descriptor, (α-β), with PAMPA playing no role (Table 4) . That is, the in vivo permeability coefficient of the zwitterion is strongly correlated to the difference between the H-bond acidity and the H-bond basicity of the molecule ("difference" H-bond effect). Excess H-bond acidity increases permeation, while excess H-bond basicity decreases it. This is an intriguing and unexpected result. Since so few in situ brain perfusion measurements are available for this class of molecules, the general robustness of the zwitterion model will require additional investigation.
The four charge-class analyses were combined into a single equation, using orthonormal indicator indices, I A , I B , I N and I Z , each of which had unit value as acids, bases, neutrals, and zwitterions, respectively, and zero otherwise:
Precisely the same MLR coefficients were determined with Eq. 6 as those in the last four rows of Figure 5 shows the IVIV correlation plot, based on Eq. 6. These results represent the most predictive BBB in vitro model published to date, as far as we are aware.
Model Validation
The multiple linear regression model developed in this study, based on Eq. 6, was validated by two variants of the leave-one-out (LOO) method, using the Algorithm Builder V1.8 program (17) . The traditional LOO approach, with repetitive MLR calculation, each time randomly taking out one measured in situ permeability, produced the q 2 =0.925. The leave-many-out (LMO) approach, where 20% of the dependent variables were randomly removed, with the MLR repeated 100 times, produced nearly the same q 2 = 0.920, with the q 2 standard deviation of 0.030. These values are only slightly less than the value of r 2 (0.930) determined by normal MLR analysis, suggesting internal robustness of the in combo model. Figure 6 shows the relationship between the in combo model predicted (Eq. 6) and observed permeability values for 85 in situ "external" set measurements not used in the training of the model. Many of the compounds in the external set comparison (Table V) are known to be substrates for efflux transporters (e.g., quinidine, paclitaxel, fexofenadine, DPDPE), especially the molecules which lie significantly below the identity line in Fig. 6 . Of note, doxorubicin in situ permeability values, which are based on data where the efflux effect was largely suppressed (verapamil, knockoutmouse models mdr1a(-/-) and mrp1(-/-)), lie above the identity line. This may hint of a possible residual uptake carrier-mediated process (11) . However, the PAMPA-BBB data for doxorubicin (and cyclosporine A) were more uncertain than that of the other molecules, due to low UV-sensitivity (cf., PAMPA errors in Table II ). The PAMPA-BBB model could suggest that molecules substantially outside of the three-fold window (dashed lines on both sides of the identity line in Figs. 5 and 6 ), might be affected by a carrier-mediated process. For newly measured com- Fig. 5 The in combo PAMPA-BBB (3 μL/well 10%w/v PBLE in alkane) based on the training set (circle symbols) based on 197 in situ intrinsic permeability values. Fig. 6 The 85 measured in situ "external" set values of compounds which could potentially be actively transported compared to those calculated from the in combo PAMPA-BBB model. Values three-fold below the identity line (marked off by the dashed line) could be indicative of efflux processes. Values three-fold above the identity line (marked off by the dashed line) could be indicative of active or carrier-mediated uptake processes. Cyclosporine A and doxorubicin may be outliers due to difficulties in evaluating the permeability from UV data. pounds with unknown mechanism of transport, having a reliable prediction of passive BBB permeability could serve to indicate the presence of carrier-mediated processes, as discussed at greater length elsewhere (11). As suggested above, cyclosporine A and doxorubicin may be considered outliers (Fig. 6 ) due to difficulties in evaluating the permeability from UV measurement.
"External" Set Comparisons
In Combo PAMPA Method Throughput
The PAMPA method described here may appear to be lowto-medium throughput, since for most of the compounds, permeability was determined in 6-12 different pH buffers (cf., Fig. 1 ). This was done to characterize the membrane contributions to permeability by eliminating the interfering effects of the ABL and the aqueous pore leakage, two effects not playing a significant role in the blood-brain barrier. Some pharmaceutical companies perform PAMPA measurements at a single pH in high-throughput assays (without stirring). To improve the throughput of the new PAMPA-BBB model, it can be proposed here that the assay be done at pH 7.4, stirring for compounds with predicted log P OCT >2, using assay time 30-60 min. For molecules with calculated log P OCT ≤2, 15 h assay time without stirring is recommended. Such a proposed procedure would have the same workload throughput as the commonly used high-throughput protocols. Taking it a step further, given that PAMPA-BBB values themselves can be predicted (e.g., pCEL-X), current prediction model can be applied entirely as a very fast in silico method, perhaps suitable for ranking molecules in virtual compound libraries.
Water Pores in PAMPA Membrane Barrier
Chen et al. (37) hypothesized a lipid/oil/lipid tri-layer structure for the BD pre-coated filter barriers. Since the void volume in the PVDF filter is calculated to be about 2.6 μL/well (88), 1 μL lipid volume used in the pre-coated plates is not enough to fully plug the filter inner volume. It is reasonable to assume that the membrane structure adopted would minimize the hexadecane-water interface surface area. The added amphiphilic phospholipid (4%w/v) would be expected to embed its acyl chains into the exposed hexadecane coating the inner filter surface, while maintaining its polar head groups in contact with the aqueous phase, reducing the surface tension, and possibly allowing some water channels to form. The earlier investigations of Thompson et al. (97) considered several pore-filling hypothetical structures, including lipid-solvent plug, lipid-solvent plug with a unilamellar bilayer, as well as multilamellar bilayers. However, the presence for any of these putative membrane structures has been difficult to substantiate for the case of PAMPA barriers formed from dilute solutions of a lecithin in an alkane solvent. Figure 7 is a hypothesized view of some of the possible domains that may form in PAMPA barriers that could support the existence of water-filled pore channels. Aqueous channel diffusion would be expected to be greater in very thin membrane barriers. The true structure of the barrier remains unknown.
CONCLUSION
The new PAMPA-BBB model based on porcine brain extract (10%w/v PBLE in alkane) can precisely mimic the physicochemical microenvironment of the BBB governing passive permeability of basic drugs, with SC=0.97±0.05, using the rodent in situ brain perfusion technique as a benchmark. For acids, SC=1.08±0.25. The neutral molecules underestimated the physicochemical selectivity of the BBB. The PAMPA-BBB model for zwitterions appeared not to correlate with the in vivo data. The in combo PAMPA-BBB technique improved the general performance of all classes of compounds, using the 197 training set in situ efflux-minimized rodent brain perfusion data (r 2 =0.93). The cross-validation LMO analysis produced a satisfactory q 2 =0.92±0.03. The comparison of the intrinsic BBB permeability of 85 "external" set BBB data to that calculated from the passive in combo PAMPA-BBB model suggested that excessive outliers could be indicative of active efflux or carrier-mediated uptake processes. Our investigation, based on a total of 282 rodent brain perfusion results, is one of the largest PS-based published study to date used to develop a BBB permeability prediction model. It was found that the thin PAMPA lipid barriers possessed water channels that allowed some paramembrane aqueous diffusion of compounds. This was an extensive shunting effect (possibly limiting the determination of low-permeable compounds and obscuring pH-dependence of permeability with ionizable compounds) of the BD pre-coated filters (1 μL lipid/well) and filters coated with 1.5 μL PAMPA-BBB lipid based on PBLE. The 3 μL-coated PAMPA-BBB filters were most robust and had the largest dynamic range window, DRW. We have thus developed a practical, lowcost, and fast quantitative method which could be used for early passive BBB permeability screening, and for assisting medicinal chemists with structure modification to improve the BBB permeability of test compounds downstream in the CNS drug discovery process. 
